Biogen (BIIB) Liabilities and Shareholders Equity (2016 - 2025)
Biogen has reported Liabilities and Shareholders Equity over the past 17 years, most recently at $29.4 billion for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $29.4 billion for Q4 2025, up 4.96% from a year ago — trailing twelve months through Dec 2025 was $115.0 billion (up 4.81% YoY), and the annual figure for FY2025 was $29.4 billion, up 4.96%.
- Liabilities and Shareholders Equity for Q4 2025 was $29.4 billion at Biogen, up from $29.2 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for BIIB hit a ceiling of $29.4 billion in Q4 2025 and a floor of $23.6 billion in Q1 2022.
- Median Liabilities and Shareholders Equity over the past 5 years was $25.9 billion (2023), compared with a mean of $26.2 billion.
- Biggest five-year swings in Liabilities and Shareholders Equity: decreased 8.67% in 2021 and later grew 13.43% in 2023.
- Biogen's Liabilities and Shareholders Equity stood at $23.9 billion in 2021, then grew by 2.83% to $24.6 billion in 2022, then grew by 9.33% to $26.8 billion in 2023, then grew by 4.49% to $28.0 billion in 2024, then grew by 4.96% to $29.4 billion in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $29.4 billion (Q4 2025), $29.2 billion (Q3 2025), and $28.3 billion (Q2 2025) per Business Quant data.